Metagenomi/$MGX
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Metagenomi
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
Ticker
$MGX
Sector
Primary listing
Employees
119
Headquarters
Website
Metagenomi Metrics
BasicAdvanced
$59M
-
-$2.36
0.47
-
Price and volume
Market cap
$59M
Beta
0.47
52-week high
$3.95
52-week low
$1.23
Average daily volume
266K
Financial strength
Current ratio
7.218
Quick ratio
7.077
Long term debt to equity
21.837
Total debt to equity
25.636
Profitability
EBITDA (TTM)
-90.696
Gross margin (TTM)
-274.59%
Net profit margin (TTM)
-348.54%
Operating margin (TTM)
-380.85%
Effective tax rate (TTM)
0.07%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-21.99%
Return on equity (TTM)
-44.67%
Valuation
Price to revenue (TTM)
2.32
Price to book
0.37
Price to tangible book (TTM)
0.37
Price to free cash flow (TTM)
-0.654
Free cash flow yield (TTM)
-152.98%
Free cash flow per share (TTM)
-2.402
Growth
Revenue change (TTM)
-51.79%
Earnings per share change (TTM)
-0.19%
3-year revenue growth (CAGR)
13.59%
3-year earnings per share growth (CAGR)
-43.13%
What the Analysts think about Metagenomi
Analyst ratings (Buy, Hold, Sell) for Metagenomi stock.
Metagenomi Financial Performance
Revenues and expenses
Metagenomi Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Metagenomi stock?
Metagenomi (MGX) has a market cap of $59M as of March 13, 2026.
What is the P/E ratio for Metagenomi stock?
The price to earnings (P/E) ratio for Metagenomi (MGX) stock is 0 as of March 13, 2026.
Does Metagenomi stock pay dividends?
No, Metagenomi (MGX) stock does not pay dividends to its shareholders as of March 13, 2026.
When is the next Metagenomi dividend payment date?
Metagenomi (MGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Metagenomi?
Metagenomi (MGX) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.